Form 4: Vaxcyte COO Jim Wassil Sells Shares Under 10b5-1 Trading Plan

Vaxcyte's Chief Operating Officer, Jim Wassil, executed sales of common stock on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 1, 2024, Jim Wassil, the Chief Operating Officer of Vaxcyte, Inc. (PCVX), sold shares of the company's common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on May 23, 2023.
• Two transactions occurred: the first involved the sale of 2,323 shares at a weighted average price of $66.531, with prices ranging from $66.09 to $67.07, and the second involved the sale of 677 shares at a weighted average price of $67.229, with prices ranging from $67.13 to $68.10.
• Following these transactions, Wassil directly owns 218,289 shares of Vaxcyte common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment towards the company's future prospects.

Industry Context

Insider selling can be interpreted in various ways by the market. It's important to consider the context of the 10b5-1 plan, which allows insiders to sell shares over a predetermined period to avoid accusations of trading on non-public information. The impact on Vaxcyte's stock will depend on overall market conditions and investor sentiment towards the company's prospects.

Stakeholder Impact

• Shareholders may react to the insider selling, although the existence of a 10b5-1 plan mitigates concerns about opportunistic trading.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal, as the stock sales do not directly affect the company's operations.

Key Dates